A. D. Beadell Investment Counsel Inc. Sells 750 Shares of Pfizer Inc. (NYSE:PFE)
A. D. Beadell Investment Counsel Inc. Sells 750 Shares of Pfizer Inc. (NYSE:PFE)
A. D. Beadell Investment Counsel Inc. lessened its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 12.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,338 shares of the biopharmaceutical company's stock after selling 750 shares during the quarter. A. D. Beadell Investment Counsel Inc.'s holdings in Pfizer were worth $279,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
據比德爾投資顧問公司在最近提交給美國證券交易委員會(美國證券交易委員會)的13F文件中稱，該公司在第二季度減持了輝瑞的股份12.3%。該基金在本季度出售了750股後，持有5338股這家生物製藥公司的股票。截至最近向美國證券交易委員會(Securities and Exchange Commission，美國證券交易委員會)提交的文件，Beadell Investment Counsel Inc.持有的輝瑞股份價值27.9萬美元。
A number of other hedge funds also recently bought and sold shares of the company. LMR Partners LLP bought a new stake in Pfizer during the 4th quarter valued at about $8,026,000. Continuum Advisory LLC increased its stake in Pfizer by 4.0% during the 4th quarter. Continuum Advisory LLC now owns 40,651 shares of the biopharmaceutical company's stock valued at $833,000 after purchasing an additional 1,561 shares in the last quarter. Baltimore Washington Financial Advisors Inc. bought a new stake in Pfizer during the 4th quarter valued at about $290,000. Red Door Wealth Management LLC increased its stake in Pfizer by 3.6% during the 4th quarter. Red Door Wealth Management LLC now owns 100,926 shares of the biopharmaceutical company's stock valued at $5,959,000 after purchasing an additional 3,552 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC increased its stake in Pfizer by 5.4% during the 4th quarter. Stonebridge Capital Advisors LLC now owns 24,968 shares of the biopharmaceutical company's stock valued at $1,474,000 after purchasing an additional 1,290 shares in the last quarter. Institutional investors own 67.90% of the company's stock.
其他一些對衝基金最近也買賣了該公司的股票。LMR Partners LLP在第四季度購買了輝瑞的新股份，價值約8,026,000美元。Continum Consulting LLC在第四季度增持了4.0%的輝瑞股份。Continum Consulting LLC現在擁有40,651股這家生物製藥公司的股票，價值833,000美元，上個季度又購買了1,561股。巴爾的摩華盛頓金融顧問公司(Baltimore Washington Financial Advisors Inc.)在第四季度新購入輝瑞股份，價值約29萬美元。紅門財富管理有限責任公司在第四季度增持輝瑞3.6%的股份。Red Door Wealth Management LLC現在持有這家生物製藥公司100,926股股票，價值5959,000美元，上個季度又購買了3,552股。最後，Stonebridge Capital Advisors LLC在第四季度增持了輝瑞5.4%的股份。Stonebridge Capital Advisors LLC現在擁有24,968股這家生物製藥公司的股票，價值1,474,000美元，上個季度又購買了1,290股。機構投資者持有該公司67.90%的股份。
Pfizer Price Performance
輝瑞的性價比
Shares of NYSE:PFE opened at $44.08 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20. Pfizer Inc. has a 1-year low of $40.94 and a 1-year high of $61.71. The company has a market capitalization of $247.39 billion, a P/E ratio of 8.63, a P/E/G ratio of 0.54 and a beta of 0.70. The firm's 50 day simple moving average is $48.24 and its two-hundred day simple moving average is $50.32.
紐約證交所：PFE的股票週五開盤報44.08美元。該公司的債務權益比為0.39，流動比率為1.42，速動比率為1.20。輝瑞公司股價跌至40.94美元的一年低點和61.71美元的一年高點。該公司市值為2,473.9億美元，市盈率為8.63，市盈率為0.54，貝塔係數為0.70。該公司的50日簡單移動均線為48.24美元，200日簡單移動均線為50.32美元。
Pfizer Announces Dividend
輝瑞宣佈分紅
The company also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer's dividend payout ratio is currently 31.31%.
該公司最近還宣佈了季度股息，將於12月5日(星期一)支付。11月4日(星期五)登記在冊的股東將獲得每股0.40美元的股息。這意味着1.60美元的年化股息和3.63%的收益率。本次股息除息日期為11月3日(星期四)。輝瑞的派息比率目前為31.31%。
Analyst Ratings Changes
分析師評級發生變化
A number of analysts have recently commented on PFE shares. Barclays set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Morgan Stanley reduced their price target on shares of Pfizer from $52.00 to $49.00 and set an "equal weight" rating for the company in a research note on Friday, July 8th. Berenberg Bank set a $44.00 price target on shares of Pfizer in a research note on Wednesday, September 14th. The Goldman Sachs Group set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Finally, UBS Group set a $59.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $57.00.
一些分析師最近對PFE的股票發表了評論。巴克萊在9月1日週四的一份研究報告中為輝瑞股票設定了50.00美元的目標價。摩根士丹利在7月8日週五的一份研究報告中將輝瑞股票的目標價從52.00美元下調至49.00美元，併為該公司設定了“同等權重”的評級。貝倫伯格銀行在9月14日星期三的一份研究報告中為輝瑞公司的股票設定了44.00美元的目標價。9月1日星期四，高盛在一份研究報告中為輝瑞設定了50美元的目標股價。最後，瑞銀集團在9月1日星期四的一份研究報告中為輝瑞股票設定了59.00美元的目標價。9名研究分析師對該股的評級為持有，10名分析師給出了買入評級，一名分析師對該股發出了強烈的買入評級。根據MarketBeat.com的數據，該公司目前的共識評級為“適度買入”，共識目標價為57.00美元。
About Pfizer
關於輝瑞公司
(Get Rating)
(獲取評級)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
輝瑞在全球發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在不同的治療領域提供藥物和疫苗，包括Premarin系列和Eiquis品牌的心血管代謝和婦女健康；Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物製品、小分子、免疫療法和生物仿製藥；舒必樂、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的無菌注射和抗感染藥物以及口服新冠肺炎治療。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 免費獲取StockNews.com關於輝瑞的研究報告
- 華爾街對Datadog的熱情會帶來巨大的收益嗎？
- MarketBeat：回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性？
- 小盤股的裁員是樓市的晴雨表嗎？
- 好市多盈利後價格疲軟是買入的好時機嗎？
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
接受輝瑞日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對輝瑞及相關公司評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。